Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study

被引:1
|
作者
Graceffa, Dario [1 ]
Zangrilli, Arianna [2 ]
Caldarola, Giacomo [3 ]
Lora, Viviana [1 ]
Orsini, Diego [1 ]
Moretta, Gala [4 ]
Pagnanelli, Gianluca [4 ]
Provini, Alessia [4 ]
Masini, Cinzia [5 ]
Bavetta, Mauro [5 ]
Giordano, Domenico [6 ]
Richetta, Antonio [7 ]
Tolino, Ersilla [8 ]
Bianchi, Luca [2 ]
Peris, Ketty [3 ]
Sperati, Francesca [9 ]
Bonifati, Claudio [1 ]
机构
[1] IRCCS, San Gallicano Dermatol Inst, Dept Clin Dermatol, Via Elio Chianesi 53, I-00144 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy
[3] Fdn Policlin Univ A Gemelli, Dipartimento Sci Med & Chirurg, UOC Dermatol, IRCCS, Rome, Italy
[4] IRCCS, Ist Dermopat Immacolata, Rome, Italy
[5] Osped San Sebastiano, UOC Dermatol, Frascati, RM, Italy
[6] Univ Rome Sapienza, St Andrea Hosp, NESMOS Dept, Dermatol Unit, Rome, Italy
[7] Univ Rome, Dept Internal Med & Med Specialties Sapienza, Unit Dermatol, Rome, Italy
[8] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Dermatol Unit Daniele Innocenzi, Rome, Italy
[9] IRCCS San Gallicano Dermatol Inst, UOSD Clin Trial Ctr, Biostat & Bioinformat, Rome, Italy
关键词
arthritis; psoriasis; risankizumab; ultrasound; DISEASE-ACTIVITY; ANKYLOSING-SPONDYLITIS; DOUBLE-BLIND; REMISSION; ENTHESITIS; ULTRASOUND;
D O I
10.1111/ijd.17156
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background IL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL-23, has proven effective on PsA in two randomized controlled trials. To date, only a few real-world data are available on this topic. Methods Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real-world setting. For this purpose, both rheumatologic and dermatologic assessments were performed at baseline and after 28-40 weeks of continuous risankizumab administration. Moreover, joint and entheses ultrasound assessment was performed at the mentioned time points. The rheumatologic assessment was carried out by means of the following scores: (i) clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA); (ii) Leeds Enthesitis Index (LEI); (iii) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and (iii) Bath Ankylosing Spondylitis Functional Index (BASFI). The degree of skin involvement was measured by both the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA). Quality of life was assessed by the Health Assessment Questionnaire (HAQ) and Dermatology Life Quality Index (DLQI). Ultrasound assessment of joints and entheses was performed on the basis of the EULAR-OMERACT score. Methods Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real-world setting. For this purpose, both rheumatologic and dermatologic assessments were performed at baseline and after 28-40 weeks of continuous risankizumab administration. Moreover, joint and entheses ultrasound assessment was performed at the mentioned time points. The rheumatologic assessment was carried out by means of the following scores: (i) clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA); (ii) Leeds Enthesitis Index (LEI); (iii) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and (iii) Bath Ankylosing Spondylitis Functional Index (BASFI). The degree of skin involvement was measured by both the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA). Quality of life was assessed by the Health Assessment Questionnaire (HAQ) and Dermatology Life Quality Index (DLQI). Ultrasound assessment of joints and entheses was performed on the basis of the EULAR-OMERACT score. Results After treatment, cDAPSA decreased from a mean value of 12.9 +/- 7.6 to 7.0 +/- 6.1 (P < 0.001), and the median PD score significantly decreased from baseline (3; range 1-8) to TP1 (1; range 0-7) (P < 0.001). PASI score also decreased from 8.4 +/- 4.9 to 0.3 +/- 0.5 (P < 0.001), and PGA from 3.1 +/- 1.0 to 0.4 +/- 0.5 (P < 0.001). ConclusionWe can conclude that risankizumab led to substantial improvement in both skin and joint involvement.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study
    A. B. Azuaga
    B. Frade-Sosa
    A. Laiz
    P. Estrada
    A. Prior-Español
    L. Horcada
    L. Polino
    M. Moreno
    C. Moragues
    A. Urruticoechea-Arana
    A. Sellas
    J. L. Tandaipan
    V. Torrente-Segarra
    J. Garcia-Miguel
    I. Ros
    S. Ordoñez
    P. Moya
    D. Reina
    L. Mateo-Soria
    C. Fito
    E. Beltrán
    M. Pujol
    A. M. Cuervo
    J. D. Cañete
    Julio Ramírez
    [J]. Clinical Rheumatology, 2020, 39 : 2963 - 2971
  • [2] Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study
    Azuaga, A. B.
    Frade-Sosa, B.
    Laiz, A.
    Estrada, P.
    Prior-Espanol, A.
    Horcada, L.
    Polino, L.
    Moreno, M.
    Moragues, C.
    Urruticoechea-Arana, A.
    Sellas, A.
    Tandaipan, J. L.
    Torrente-Segarra, V.
    Garcia-Miguel, J.
    Ros, I.
    Ordonez, S.
    Moya, P.
    Reina, D.
    Mateo-Soria, L.
    Fito, C.
    Beltran, E.
    Pujol, M.
    Cuervo, A. M.
    Canete, J. D.
    Ramirez, Julio
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (10) : 2963 - 2971
  • [3] Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
    Elgaard, Cathrine Dawn Buttner
    Iversen, Lars
    Hjuler, Kasper Fjellhaugen
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [4] Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
    Smolen, Josef
    Athanassiou, Panagiotis
    Bergmans, Paul
    Bondareva, Irina
    De Vlam, Kurt
    Gremese, Elisa
    Joven-Ibanez, Beatriz
    Korotaeva, Tatiana
    Noel, Wim
    Nurmohamed, Michael
    Kakis, Petros Sfi
    Siebert, Stefan
    Smirnov, Pavel
    Theander, Elke
    Gossec, Laure
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [5] Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
    Alegre-Sancho, Juan Jose
    Nunez-Monje, Victoria
    Campos-Fernandez, Cristina
    Balaguer-Trull, Isabel
    Robustillo-Villarino, Montserrat
    Aguilar-Zamora, Marta
    Garijo-Bufort, Marta
    Pedraz-Penalva, Teresa
    Pena-Gonzalez, Carolina
    de la Morena, Isabel
    Bedoya-Sanchis, Diego
    Yankova-Komsalova, Liliya
    Conesa-Mateos, Arantxa
    Martinez-Cristobal, Anna
    Navarro-Blasco, Francisco Javier
    Senabre-Gallego, Jose Miguel
    Sivera, Francisca
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [6] Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
    Bessette, Louis
    Rahman, Proton
    Choquette, Denis
    Kelsall, John
    Sheriff, Maqbool
    Rampakakis, Emmanouil
    Psaradellis, Eliofotisti
    Lehman, Allen J.
    Maslova, Karina
    Nantel, Francois
    Osborne, Brendan
    Tkaczyk, Cathy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH PSORIATIC ARTHRITIS
    Choi, J.
    Sreih, A.
    Lehman, T.
    Suryavanshi, M.
    Xia, Q.
    Nowak, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1564 - 1565
  • [8] Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study
    Dattola, A.
    Balato, A.
    Megna, M.
    Gisondi, P.
    Girolomoni, G.
    De Simone, C.
    Caldarola, G.
    Cama, E.
    Piaserico, S.
    Fargnoli, M. C.
    Fidanza, R.
    Parodi, A.
    Burlando, M.
    Offidani, A.
    Diotallevi, F.
    Potenza, C.
    Conti, A.
    Chiricozzi, A.
    Campione, E.
    Bianchi, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) : 2839 - 2845
  • [9] REAL-WORLD EFFECTIVENESS AND SAFETYOF SECUKINUMAB IN AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS
    Astigarraga Urquia, Uxue
    Gomez, Marta Lopez I.
    Ibarrola, Libe
    Pineiro, Irene
    Mendizabal, Javier
    Sada Urdameneta, Guillen
    Del Val Del Amo, Natividad
    Paniagua Zudaire, Inmaculada
    Garrido Courel, Laura
    Fito Manteca, Concepcion
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S104 - S105
  • [10] Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
    Elgaard, Cathrine Dawn Buttner
    Iversen, Lars
    Hjuler, Kasper Fjellhaugen
    [J]. DRUGS IN R&D, 2023, 23 (02) : 155 - 163